Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist

被引：2

作者：

Baska, Ferenc ^{[1
]}

Bozo, Eva ^{[1
]}

Szeleczky, Zsolt ^{[1
]}

Szanto, Gabor ^{[1
]}

Vukics, Krisztina ^{[1
]}

Szakacs, Zoltan ^{[1
]}

Domany-Kovacs, Katalin ^{[1
]}

Kurko, Dalma ^{[1
]}

Vass, Elemer ^{[2
]}

Than, Marta ^{[1
]}

Vastag, Monika ^{[1
]}

Temesvari, Krisztina ^{[1
]}

Levai, Sandor ^{[1
]}

Halasz, Attila Sandor ^{[1
]}

Kordas, Krisztina Szondine ^{[1
]}

Roman, Viktor ^{[1
]}

Greiner, Istvan ^{[1
]}

Bata, Imre ^{[1
]}

机构：

[1] Gedeon Richter Plc, H-1475 Budapest, Hungary

[2] Eotvos Lorand Univ, Inst Chem, H-1117 Budapest, Hungary

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 01期

关键词：

RANDOMIZED CONTROLLED-TRIAL; AUTISM SPECTRUM DISORDERS; VASOPRESSIN V1A; ACTIVE METABOLITE; BALOVAPTAN; PHARMACOKINETICS; PAZINACLONE; INHIBITION; SR-49059; SINGLE;

D O I：

10.1021/acs.jmedchem.3c01868

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The V1a receptor is a major contributor in mediating the social and emotional effects of arginine-vasopressin (AVP); therefore it represents a promising target in the treatment of several neuropsychiatric conditions. The aim of this research was to design and synthesize novel and selective V1a antagonists with improved in vitro and in vivo profiles. Through optimization and detailed SAR studies, we developed low nanomolar antagonists, and further characterizations led to the discovery of the clinical candidate compound 43 (RGH-122). The CNS activity of the compound was determined in a 3-chamber social preference test of autism in which RGH-122 successfully enhanced social preference with the lowest effective dose of 1.5 mg/kg.

引用

页码：643 / 673

页数：31

共 50 条

[21] Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2
Xue, Chu-Biao
Wang, Anlai
Meloni, David
Zhang, Ke
Kong, Ling
Feng, Hao
Glenn, Joseph
Huang, Taisheng
Zhang, Yingxin
Cao, Ganfeng
Anand, Rajan
Zheng, Changsheng
Xia, Michael
Han, Qi
Robinson, D. J.
Storace, Lou
Shao, Lixin
Li, Mei
Brodmerkel, Carrie M.
Covington, Maryanne
Scherle, Peggy
Diamond, Sharon
Yeleswaram, Swamy
Vaddi, Kris
Newton, Robert
Hollis, Greg
Friedman, Steven
Metcalf, Brian
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (24) : 7473 - 7478
[22] Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1
Liang, M
Mallari, C
Rosser, M
Ng, HP
May, K
Monahan, S
Bauman, JG
Islam, I
Ghannam, A
Buckman, B
Shaw, K
Wei, GP
Xu, W
Zhao, Z
Ho, E
Shen, J
Oanh, H
Subramanyam, B
Vergona, R
Taub, D
Dunning, L
Harvey, S
Snider, RM
Hesselgesser, J
Morrissey, MM
Perez, HD
Horuk, R
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (25) : 19000 - 19008
[23] Discovery of a novel, orally bioavailable CGRP receptor antagonist for the treatment of migraine
Bell, Ian M.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 237
[24] Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist
Kim, Seon-Mi
Lee, Minhee
Lee, So Young
Park, Euisun
Lee, Soo-Min
Kim, Eun Jeong
Han, Min Young
Yoo, Taekyung
Ann, Jihyae
Yoon, Suyoung
Lee, Jiyoun
Lee, Jeewoo
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) : 9150 - 9172
[25] Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
Wang, Zhulun
Sun, Daqing
Johnstone, Sheree
Cao, Zhaodan
Gao, Xiong
Jaen, Juan C.
Liu, Jingqian
Lively, Sarah
Miao, Shichang
Sudom, Athena
Tomooka, Craig
Walker, Nigel P. C.
Wright, Matthew
Yan, Xuelei
Ye, Qiuping
Powers, Jay P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (23) : 5546 - 5550
[26] ORGN 54-Discovery of potent, selective, and orally bioavailable antagonists of CC Chemokine Receptor 2
Carter, Percy H.
Brown, Gregory D.
Nelson, David J.
Cherney, Robert J.
Duncia, John V.
Santella, Joseph B., III
Gardner, Daniel S.
Cvijic, Mary Ellen
Mandlekar, Sandhya
Tebben, Andrew J.
Zhao, Qihong
Decicco, Carl P.
Barrish, Joel C.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
[27] Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist
Tsukuda, J
Tahara, A
Tomura, Y
Wada, K
Kusayama, T
Ishii, N
Aoki, M
Yatsu, T
Uchida, W
Taniguchi, N
Tanaka, A
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 446 (1-3) : 129 - 138
[28] Discovery of potent, selective and orally bioavailable growth hormone secretagogue receptor (Ghs-R) antagonists
Xin, ZL
Serby, MD
Zhao, HY
Liu, M
Liu, B
Hutchins, CW
Sarris, K
Ethan, H
Falls, DH
Collins, CA
Lin, CW
Ogiela, CA
Brune, ME
Bush, G
Droz, B
Fey, T
Knourek-Segel, V
Shapiro, R
Jacobson, P
Beno, D
Turner, T
Sham, HL
Liu, G
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2544 - U2544
[29] Medicinal chemistry discovery of the clinical candidate AZD9496: A potent and orally bioavailable selective estrogen receptor down-regulator and antagonist
De Savi, Chris
Bradbury, Rob
Rabow, Alfred
Norman, Richard
Buttar, David
Currie, Gordon
Donald, Craig
Hayter, Barry
MacFaul, Philip
Ballard, Peter
Pearson, Stuart
Moss, Thomas
Lamont, Scott
Feron, Lyman
Glossop, Steven
Davies, Chris
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[30] The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine
Lin, Peter
Chang, Lehua
DeVita, Robert J.
Young, Jonathan R.
Eid, Ronsar
Tong, Xinchun
Zheng, Song
Ball, Richard G.
Tsou, Nancy N.
Chicchi, Gary G.
Kurtz, Marc M.
Tsao, Kwel-Lan C.
Wheeldon, Alan
Carlson, Emma J.
Eng, WaiSi
Burns, H. Donald
Hargreaves, Richard J.
Mills, Sander G.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (18) : 5191 - 5198

← 1 2 3 4 5 →